Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer's disease progression.

Authors

Guoyu Lan, Wang Liao, Mingxing Jiang, Jiayi Zhu, Wenqing Ran, Fernando Gonzalez-Ortiz, Xiang Fan, Hongjie Yang, Dai Shi, Laihong Zhang, Anqi Li, Yue Cai, Pan Sun, Zhengbo He, Xin Zhou, Jie Yang, Yalin Zhu, Mingxu Li, Wenjing Huang, Binhui Liu, Yiying Wang, Xinyue Ma, Rong Ma, Yimei Zhang, Chao Huang, Zhen Liu, Qingyong Wang, Liemin Zhou, Fang Xie, Ying Han, Zhen Liang, Xuhui Chen, Mengjie Dong, Guanxun Cheng, Lu Wang, Benyan Luo, Yan-Jiang Wang, Xiaochun Chen, Alzheimer's Disease Neuroimaging Initiative, Jiawei Xin, Guoping Peng, Tengfei Guo

Published in

Alzheimer's & dementia : the journal of the Alzheimer's Association. Volume 22. Issue 9. Pages e71783.

Abstract

Longitudinal diagnostic and prognostic validity of plasma phosphorylated tau217 (p-tau217) in Alzheimer's disease (AD) remains uncertain.
In this multi-cohort study of 2117 individuals, we established baseline plasma p-tau217 thresholds for amyloid-β-positron emission tomography (Aβ-PET) and assessed their longitudinal classification stability and prognostic relevance for AD-related outcomes.
Baseline-defined cutoffs achieved high and sustained accuracy (86%-95%) for Aβ-PET positivity over up to 5 years of follow-up. Longitudinally, most p-tau217-positive individuals remained stable (93%-98%), whereas the intermediate zone group progressed more to positive (44%-78%) than p-tau217-negative individuals (4%-21%). Participants with stable-positive and progress-to-positive p-tau217 profiles more frequently exhibited Aβ abnormalities (90%-100% and 64%-96%, respectively) and experienced accelerated tau accumulation, hippocampal atrophy, and incident dementia compared to those with a stable-negative p-tau217 profile.
These findings support the high stability and Aβ-PET classification performance of longitudinal plasma p-tau217 monitoring in AD, providing a scalable tool for risk stratification and disease monitoring.

PMID:
42669630
Bibliographic data and abstract were imported from PubMed on 31 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.